These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 7699581)
1. [Pharmacological profile of F-0401, a novel dihydropyridine derivative. III. The anti-aggregatory action of F-0401 on rabbit platelets]. Kase N; Tamura N; Yamaura T; Ohnishi H Yakugaku Zasshi; 1995 Jan; 115(1):52-61. PubMed ID: 7699581 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacological profile of F-0401, a novel dihydropyridine derivative. (1) Mechanisms of action]. Kase N; Takasaki K; Higashide Y; Tamura N; Lee B; Yamaura T; Ohnishi H Nihon Yakurigaku Zasshi; 1993 Jun; 101(6):363-74. PubMed ID: 8340021 [TBL] [Abstract][Full Text] [Related]
3. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
4. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives. Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of the Korean herbal medicine, Dae-Jo-Whan, on platelet-activating factor-induced platelet aggregation. Chang GT; Kang SK; Kim JH; Chung KH; Chang YC; Kim CH J Ethnopharmacol; 2005 Dec; 102(3):430-9. PubMed ID: 16125889 [TBL] [Abstract][Full Text] [Related]
6. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979 [TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo. Yue TL; Rabinovici R; Farhat M; Feuerstein G J Lipid Mediat; 1991; 3(1):13-26. PubMed ID: 1768837 [TBL] [Abstract][Full Text] [Related]
8. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate. Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011 [TBL] [Abstract][Full Text] [Related]
9. Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505. Pons F; Rossi AG; Norman KE; Williams TJ; Nourshargh S Br J Pharmacol; 1993 May; 109(1):234-42. PubMed ID: 8495241 [TBL] [Abstract][Full Text] [Related]
10. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies. Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624 [TBL] [Abstract][Full Text] [Related]
11. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine. Fray MJ; Bull DJ; Cooper K; Parry MJ; Stefaniak MH J Med Chem; 1995 Sep; 38(18):3524-35. PubMed ID: 7658439 [TBL] [Abstract][Full Text] [Related]
12. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676 [TBL] [Abstract][Full Text] [Related]
15. [Effects of ketotifen on rabbit platelet aggregation and platelet activating factor formation from rat neutrophils]. Wang XD; Bian RL Zhongguo Yao Li Xue Bao; 1990 Nov; 11(6):524-7. PubMed ID: 2130617 [TBL] [Abstract][Full Text] [Related]
16. Anti-thrombotic and anti-inflammatory activities of protopine. Saeed SA; Gilani AH; Majoo RU; Shah BH Pharmacol Res; 1997 Jul; 36(1):1-7. PubMed ID: 9368908 [TBL] [Abstract][Full Text] [Related]
17. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists. Sunkel CE; de Casa-Juana MF; Santos L; Gómez MM; Villarroya M; González-Morales MA; Priego JG; Ortega MP J Med Chem; 1990 Dec; 33(12):3205-10. PubMed ID: 2175357 [TBL] [Abstract][Full Text] [Related]
18. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding. Herbert JM; Laplace MC; Maffrand JP J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264 [TBL] [Abstract][Full Text] [Related]
19. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets. Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330 [TBL] [Abstract][Full Text] [Related]
20. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]